MedX Health Management

Management criteria checks 2/4

MedX Health's CEO is Stephen Lockyer, appointed in May 2023, has a tenure of less than a year. directly owns 9.44% of the company’s shares, worth CA$2.47M. The average tenure of the management team and the board of directors is 2.8 years and 5.9 years respectively.

Key information

Stephen Lockyer

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	9.4%
Management average tenure	2.8yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

CEO

Stephen Lockyer

less than a year

Tenure

Mr. Stephen Lockyer serves as Director of MedX Health Corp since April 12, 2023 and serves as its Chief Executive Officer since May 11, 2023. He co founded Cornwallis Financial Corporation and serves as it...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Christopher Freeman	Corporate Secretary & Acting CFO	2yrs	CA$14.93k	no data
Michael Druhan	President of Dermatological Services & Products	3.6yrs	CA$273.52k	no data
Stephen Lockyer	CEO & Director	less than a year	no data	9.44% CA$ 2.5m
Scott Naughton	Managing Director of US Operations	7.3yrs	no data	no data

2.8yrs

Average Tenure

Experienced Management: MDX's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Stephen Lockyer	CEO & Director	less than a year	no data	9.44% CA$ 2.5m
David Henniger	Independent Vice Chairman	22.4yrs	no data	1.36% CA$ 355.2k
Kenneth McKay	Independent Chairman	22.4yrs	no data	0.33% CA$ 86.8k
Daniel Siegel	Member of Medical Advisory Board	5.9yrs	no data	no data
Dennis Reich	Member of Medical Advisory Board	7.2yrs	no data	no data
Trevor Champagne	Chairman of Medical Advisory Board	5.7yrs	no data	no data
Joe Walls	Member of Medical Advisory Board	no data	no data	no data
Per Hall	Member of Medical Advisory Board	no data	no data	no data
Edmund Ho	Independent Director	less than a year	no data	4.67% CA$ 1.2m

5.9yrs

Average Tenure

72yo

Average Age

Experienced Board: MDX's board of directors are considered experienced (5.9 years average tenure).

MedX Health Management

Management criteria checks 2/4

Key information

Recent management updates

CEO & Director exercised options to buy CA$1.3m worth of stock.

MedX Health Corp Announces Resignation of Naman Damaghlatrous as Director

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

New major risk - Share price stability

Third quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.006 loss in 3Q 2022)

CEO & Director exercised options to buy CA$1.3m worth of stock.

MedX Health Corp announced that it has received CAD 1.02 million in funding

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding

New minor risk - Shareholder dilution

Second quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2022)

New major risk - Share price stability

First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 1Q 2022)

MedX Health Corp Announces Resignation of Naman Damaghlatrous as Director

Full year 2022 earnings released: CA$0.028 loss per share (vs CA$0.03 loss in FY 2021)

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding from Forest Lane Holdings Limited

Third quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 3Q 2021)

MedX Health Corp announced that it expects to receive CAD 1.5 million in funding from Forest Lane Holdings Limited

Second quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.007 loss in 2Q 2021)

MedX Health Corp announced that it expects to receive CAD 4 million in funding

Full year 2021 earnings released: CA$0.03 loss per share (vs CA$0.019 loss in FY 2020)

MedX Health Corp announced that it expects to receive CAD 4 million in funding

Third quarter 2021 earnings: EPS in line with analyst expectations despite revenue beat

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Chairman of the Board Robert von der Porten has left the company

Second quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.004 loss in 2Q 2020)

COO & MD of Light Therapy Products recently sold CA$53k worth of stock

First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.005 loss in 1Q 2020)

MedX Health Corp announced that it expects to receive CAD 2.5 million in funding

Full year 2020 earnings released: CA$0.019 loss per share (vs CA$0.023 loss in FY 2019)

MedX Health Corp. Announces Retirement of Board Members

EMPOWER CLINICS INC. and MedX Health Corporation Announce Memorandum of Understanding to Pilot MedX's Leading-Edge DermSecure Screening Platform At Two Select Empower Clinics Locations in Ontario

MedX Health Corp. Announces the Appointment of Paul Karam as Sales and Marketing Director for Europe, Middle East, Africa (EMEA)

New 90-day high: CA$0.24

MedX Health Corp announced that it expects to receive CAD 4 million in funding

MedX Health Corporation Appoints Trevor Champagne as Chair Medical Advisory Board

Medx Health Corp. Announces the Rollout of DermSecure in the Netherlands

Third quarter 2020 earnings released: CA$0.006 loss per share

MedX Health Corp Announces Board Changes

Medx Health Corp. Appoints Anthony Milonas and Wayne Cockburn as Directors

First half earnings released

MedX Health Corp. Announces Management Appointments

MedX Health Corp announced that it expects to receive CAD 2 million in funding

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age